Please assess the completion status of the following clinical trial:

Trial Title: Impact of Metabolic Syndrome on Flu Vaccine Efficacy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for the METABOLIC SYNDROME COHORT( Participants must have 3 or more of the following 5 risk factors):~* Abdominal Obesity, given as a waist circumference: Men \>102 cm (\>40 in) Women \> 88 cm (\>35 in)~* Triglycerides \>150 mg/dl~* HDL Cholesterol: Men \< 40 mg/dl Women \< 50 mg/dl~* Blood Pressure \>130/ \>85 mm Hg - or controlled on antihypertensive medication~* Fasting Glucose \> 100 mg/dl~Inclusion criteria for the HEALTHY CONTROLS (Participants must have all of the requirements below) :~* body mass index 18.5 - 25 kg/m2~* HDL female \> 50 mg/dL, male \> 40 mg/dL~* fasting glucose \< 100 mg/dL~* triglycerides \<150 mg/dL,~* waist circumference of a female \< 88 cm, male \< 102 cm)~* - Blood pressure \< or = to 120/80 (based on an average of 3 readings taken 5 minutes apart after the consent form has been signed)~Exclusion criteria :~* Currently undergoing treatment for the metabolic syndrome~* The average of 2 BP readings \> 150/90 (based on 2 B/Ps taken at screening visit 1).~* Hepatitis A, B and C~* NSAIDs and/or Aspirin ingestion within the last 14 days~* Self-reported history of any active autoimmune diseases~* Self-reported ingestion of statins within the last 3 months~* Self-reported antibiotic use within the last 3 months~* Anti-inflammatory drugs including biologics and corticosteroids within last 3 months( nasal spray and topical applications are OK)or Omega 3 Fatty Acids.~* Self-reported hx of cancer treatment within the last year~* Allergy to eggs~* History of Guillain-Barre syndrome~* Pregnant ( determined by point of care testing at screening visit 1).~* HIV positive~* Self-reported history of flu vaccination within the past 3 months.~* Any self-reported infection in the week of the visit except the first two visits (Screening visit 1 and Screening visit 2) and the last visit (Study visit #5) that could be rescheduled.~* Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.~Study Population Description The population from which the groups will be selected are resident of New York City.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Influenza vaccine in metabolic syndrome (Type: EXPERIMENTAL): Influenza vaccine
- Influenza vaccine in healthy controls (Type: EXPERIMENTAL): Influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).